Pamela Stephenson Net Worth

The estimated Net Worth of Pamela Stephenson is at least $5.58 Million dollars as of 13 June 2023. Ms. Stephenson owns over 115 units of Albireo Pharma Inc stock worth over $3,345,599 and over the last 6 years she sold ALBO stock worth over $274,922. In addition, she makes $1,963,390 as Chief Commercial Officer at Albireo Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Stephenson ALBO stock SEC Form 4 insiders trading

Pamela has made over 20 trades of the Albireo Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 115 units of ALBO stock worth $40 on 13 June 2023.

The largest trade she's ever made was selling 1,785 units of Albireo Pharma Inc stock on 25 March 2020 worth over $31,416. On average, Pamela trades about 306 units every 38 days since 2019. As of 13 June 2023 she still owns at least 75,778 units of Albireo Pharma Inc stock.

You can see the complete history of Ms. Stephenson stock trades at the bottom of the page.

Pamela Stephenson biography

Pamela Stephenson serves as Chief Commercial Officer of the Company. She previously served as Vice President at Vertex Pharmaceuticals Incorporated, a publicly traded biopharmaceutical company, from July 2008 to March 2019, where she was responsible for leading the global market access and pricing strategy for Vertex's current and future products and where she oversaw the Health Economics & Outcomes Research and the Global Pricing & Market Access teams and was a member of the Commercial Leadership Team that guides the global commercial strategy for Vertex. Previously, Ms. Stephenson served as Vice President of Cystic Fibrosis Marketing and Patient Services at Vertex, where she led the U.S. launch of Orkambi® (lumacaftor/ivacaftor). She also led the launch of Vertex's first commercial product, Incivek® (telaprevir) for Hepatitis C. The Incivek team received the Prix Galien Award for Best Pharmaceutical Product in 2012. Prior to Vertex, Pamela was with Pfizer for 10 years in roles of increasing strategic importance, and led marketing efforts for brands such as Viagra® (sildenafil citrate) and Aromasin® (exemestane). Ms. Stephenson also serves on the board of directors of Zynerba Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. She has a B.A. from Brown University and an MPH from Boston University School of Public Health.

What is the salary of Pamela Stephenson?

As the Chief Commercial Officer of Albireo Pharma Inc, the total compensation of Pamela Stephenson at Albireo Pharma Inc is $1,963,390. There are 1 executives at Albireo Pharma Inc getting paid more, with Ronald Cooper having the highest compensation of $2,995,410.

How old is Pamela Stephenson?

Pamela Stephenson is 52, she's been the Chief Commercial Officer of Albireo Pharma Inc since 2019. There are 18 older and 2 younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.

What's Pamela Stephenson's mailing address?

Pamela's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.

Insiders trading at Albireo Pharma Inc

Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs, and Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.

What does Albireo Pharma Inc do?

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Complete history of Ms. Stephenson stock trades at Albireo Pharma Inc and Zynerba Pharmaceuticals Inc

Albireo Pharma Inc executives and stock owners

Albireo Pharma Inc executives and other stock owners filed with the SEC include:

• Ronald Cooper,
  President, Chief Executive Officer, Director
• Pamela Stephenson,
  Chief Commercial Officer
• Jan Mattsson,
  Chief Scientific Officer
• Martha Carter,
  Chief Regulatory Officer
• Ronald H. W. Cooper,
  CEO, Pres & Director
• Patrick Horn,
  Chief Medical Officer
• Martha J. Carter,
  Chief Regulatory Officer
• Simon Nicolas Reade Harford,
  CFO & Treasurer
• David Chiswell,
  Independent Chairman of the Board
• Davey Scoon,
  Independent Director
• Michael Gutch,
  Independent Director
• Roger Jeffs,
  Independent Director
• Stephanie Okey,
  Independent Director
• Anne Klibanski,
  Independent Director
• Jason Duncan,
  Chief Legal Officer, General Counsel, Secretary
• Michelle Graham,
  Chief Human Resource Officer
• Simon Harford,
  Chief Financial Officer, Treasurer
• Jason G. Duncan,
  Chief Legal Officer, Gen. Counsel & Sec.
• Pamela Stephenson M.P.H.,
  Chief Commercial Officer
• Dr. Kristina Torfgard,
  VP & Global Project Head
• Michelle Graham,
  Chief HR Officer
• Joan Connolly,
  Chief Technology Officer
• Dr. Jan P. Mattsson Ph.D.,
  Chief Scientific Officer, MD (Sweden) & Co-Founder
• Dr. Per-Goran Gillberg,
  Co-Founder & VP of Devel.
• Denise Scots Knight,
  Director
• Julia R Brown,
  Director
• Heather Preston,
  Director
• Paresh Soni,
  Chief Medical Officer
• Thomas A. Shea,
  CFO and Treasurer
• Peter A Zorn,
  Senior VP, Corp Dev, GC & Sec
• Plcastrazeneca Ab Astrazeneca,
  
• Paul Streck,
  Chief Medical Officer
• Advisors Llcperceptive Life...,
  
• Partners Ltd Phase4 Venture...,
  
• Craig C. Hopkinson,
  Director
• Susan Alesina,
  Director
• Habib J Dable,
  Director